Genmab — Oktober 2020

[Bulder]

Hvorfor ikke kombineres med epco?

[GeorgeBest]

Selvfølgelig

[Bulder]

De er begge sc den ene i maven - den anden i låret. Hvor svært kan det være?

[GeorgeBest]

[E_L]

Friday rumour is that you will be able to mix Hexabody-CD38 into a beer bottle. It will be a real breaktrough in drug administration. You heard it here first!

[Bullish]

I volunteer for the control group

[E_L]

[nohope]

He
xaneken 3,8% ?

[DevOp]

anything below 7-8% after a week like this is discarded

[Bulder]

Men bortset fra det, så blev dara jo klinisk testet i NHL for år tilbage med skuffelse til følge. Tvivler på, det bliver taget op igen. https://www.mdedge.com/hematology-oncology/article/194227/mantle-cell-lymphoma/daratumumab-disappoints-non-hodgkin-lymphoma

[E_L]

yes, it will be for the next generation i think, Hexabody-CD38 will be tested in DLBCL

[Helge_LarsenPI-redaktør]

I lige måde.

[Helge_LarsenPI-redaktør]

Genmab
@Genmab
·
2 t
Close collaboration with top research institutions is part of our DNA at Genmab. We are excited to announce our new partnership with @PrincetonChem
, which will pair experts in academia and our researchers to explore new areas of antibody research: https://chemistry.princeton.edu/news/pci-signs-agreement-genmab-forge-strong-community-bond

[GeorgeBest]

A Phase 1/2, Open-Label, Dose-Escalation
Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma

[GeorgeBest]

https://www.bloodcancerwa.org.au/trial/gct-3013-01/

[Helge_LarsenPI-redaktør]

Stoxx: Europæiske health care aktier fortsat under pres pgr af ventet Biden sejrhttps://www.proinvestor.com/investornyt/668932/stoxx-europaeiske-health-care-aktier-fortsat-under-pres-pgr-af-ventet-biden-sejr

[E_L]

Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64–labeled daratumumab https://ashpublications.org/bloodadvances/article/4/20/5194/469709/Identifying-CD38-cells-in-patients-with-multiple

[E_L]

Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study https://www.nature.com/articles/s41408-020-00369-0

[E_L]

table 3: https://www.nature.com/articles/s41408-020-00369-0/tables/3 Keratopathy 96% any grade, 75% (!) grade 3 or 4

[Bulder]

... "all patients were exposed to bortezomib, lenalidomide, pomalidomide and daratumumab, and 80% of patients were exposed to carfilzomib." Thus for heavily pretreated pt
s refrsc